Company
TG Therapeutics
TG Therapeutics has 13 drugs tracked on RxWires: 1 post-market, 1 approved, 1 in Phase 3, 3 in Phase 2, 1 in Phase 1/2, 6 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| Ublituximab | Post-Market | Multiple Sclerosis |
| PHENTERMINE HYDROCHLORIDE | Approved | |
| Obinutuzumab | Phase 3 | Chronic Lymphocytic Leukemia |
| Umbralisib | Phase 2 | Chronic Lymphocytic Leukemia |
| TGR-1202 | Phase 2 | Follicular Lymphoma |
| Acalabrutinib | Phase 2 | Chronic Lymphocytic Leukemia |
| Venetoclax | Phase 1/2 | Chronic Lymphocytic Leukemia |
| Azercabtagene zapreleucel (azer-cel) | Phase 1 | B-cell Mediated Autoimmune Disorders |
| Cosibelimab | Phase 1 | B-cell Non Hodgkin Lymphoma |
| TG-1801 | Phase 1 | CLL |
| TGR-1202 + Obinutuzumab + Chlorambucil | Phase 1 | Chronic Lymphocytic Leukemia |
| TG-1701 | Phase 1 | Non Hodgkin Lymphoma |
| TGR-1202 + brentuximab vedotin | Phase 1 | Hodgkin's Lymphoma |
Latest
- tg therapeutics filed 8-K
- tg therapeutics filed 8-K
- tg therapeutics filed 8-K
- tg therapeutics filed 8-K
- tg therapeutics filed 8-K
Follow TG Therapeutics on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.